COMPANY
Apellis Pharmaceuticals, Inc.
FDA-approved therapeutic company Clinical Phase 3
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Hematology (PNH) Account Manager - Mountain West | US - Field | Oct 20, 2026 | Oct 8, 2026 |
| Director, Global Supply Operations | US - Cambridge | Oct 19, 2026 | Oct 20, 2026 |
| Sr. Manager, Commercial Learning & Development – Operations | US - Remote | Oct 13, 2026 | Oct 14, 2026 |
| Account Manager, Nephrology, San Diego/Inland Empire | US - Field | Oct 5, 2026 | Oct 8, 2026 |
| Product Manager, US Patient Marketing – EMPAVELI | US - Cambridge | Sep 29, 2026 | Oct 8, 2026 |
Timeline
- Trial start 2: A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis source ↗
- Board tracked Radar started tracking this company’s job board (18 open jobs at last check). source ↗
- Trial start Phase 3: Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation source ↗
- Trial start Phase 3: Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe source ↗
- FDA FDA New indication / efficacy supplement: EMPAVELI (pegcetacoplan) — NDA215014/11, Jul 28, 2025. Applicant at approval: Apellis Pharmaceuticals, Inc. source ↗
- Trial start 2: A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetaco source ↗
- Trial start 4: A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atroph source ↗
- Trial start Phase 3: An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproli source ↗
- Trial start —: Geographic Atrophy Long-Terms Outcomes Study source ↗
- Trial start III: Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis source ↗
- Trial start Phase 2: Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN source ↗
- Trial start Phase 3: An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD source ↗
- Trial start Phase 2: A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) source ↗
- Trial start Phase 2: MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) source ↗
- Trial start Phase 1/Phase 2: A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 source ↗
- Trial start Phase 3: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH source ↗
- Trial start Phase 1: Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy source ↗
- Trial start Phase 3: A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration source ↗
- Trial start Phase 3: Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration source ↗
- Trial start Phase 3: Pegcetacoplan Long Term Safety and Efficacy Extension Study source ↗
- Trial start II: A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH source ↗
- Trial start Phase 3: Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) source ↗
- Trial start II: Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies source ↗
- Trial start Phase 1/Phase 2: Pegcetacoplan (APL-2) in Neovascular AMD source ↗
- Trial start Phase 2: Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) source ↗
Upcoming milestones
- 2027-06 (ESTIMATED) · 4 · A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy S · NCT06161584
- Jun 25, 2027 (ESTIMATED) · 2 · A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacopla · NCT07215390
- 2027-07 (ESTIMATED) · Phase 3 · An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative · NCT05809531
- 2028-12 (ESTIMATED) · Phase 2 · A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) · NCT04901936
- 2029-10 (ESTIMATED) · 2 · A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis · NCT07213960
Open jobs 18
Clinical trials (lead sponsor) 28
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07020832 | Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation | Phase 3 | Withdrawn | May 18, 2026 | 2029-06 (estimated) |
| NCT07213960 | A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis | 2 | Recruiting | 2026-12 | 2029-10 (estimated) |
| NCT04901936 | A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Recruiting | Feb 4, 2021 | 2028-12 (estimated) |
| NCT07215390 | A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio | 2 | Recruiting | Jun 23, 2025 | Jun 25, 2027 (estimated) |
| NCT04770545 | An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD | Phase 3 | Completed | Mar 4, 2021 | Sep 5, 2025 (actual) |
| NCT03531255 | Pegcetacoplan Long Term Safety and Efficacy Extension Study | Phase 3 | Completed | Aug 27, 2018 | Sep 4, 2025 (actual) |
| NCT06161584 | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | 4 | Active, not recruiting | Sep 28, 2023 | 2027-06 (estimated) |
| NCT04572854 | Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN | Phase 2 | Completed | Sep 7, 2021 | Feb 27, 2023 (actual) |
| NCT05809531 | An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis | Phase 3 | Active, not recruiting | May 29, 2023 | 2027-07 (estimated) |
| NCT05067127 | Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis | III | Completed | Nov 12, 2021 | Jun 26, 2024 (actual) |
| NCT07214740 | Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe | Phase 3 | Completed | Oct 24, 2025 | Dec 12, 2025 (actual) |
| NCT04729062 | C3G/Primary IC-MPGN EAP | Not listed | Approved for marketing | Not listed | Not listed |
| NCT04579666 | MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Terminated | Sep 30, 2020 | Mar 31, 2023 (actual) |
| NCT03453619 | Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies | II | Completed | Feb 26, 2018 | Apr 16, 2020 (actual) |
| NCT03226678 | Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) | Phase 2 | Completed | Aug 31, 2017 | Sep 12, 2022 (actual) |
| NCT06499571 | Geographic Atrophy Long-Terms Outcomes Study | Not listed | Completed | Sep 1, 2022 | Jul 31, 2023 (actual) |
| NCT03525613 | A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration | Phase 3 | Completed | Aug 31, 2018 | Jun 28, 2021 (actual) |
| NCT03525600 | Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration | Phase 3 | Completed | Aug 31, 2018 | Jun 21, 2021 (actual) |
| NCT04085601 | A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH | Phase 3 | Completed | Aug 27, 2019 | Jun 23, 2021 (actual) |
| NCT03500549 | Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | Completed | Jun 14, 2018 | Nov 14, 2019 (actual) |
| NCT04402060 | A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 | Phase 1/Phase 2 | Completed | May 28, 2020 | Feb 13, 2021 (actual) |
| NCT03777332 | Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy | Phase 1 | Completed | Nov 5, 2018 | Apr 1, 2021 (actual) |
| NCT02588833 | Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects. | Phase 1 | Completed | Dec 1, 2015 | Aug 26, 2019 (actual) |
| NCT02264639 | A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH | I | Completed | Feb 23, 2015 | Oct 22, 2018 (actual) |
| NCT03593200 | A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH | II | Completed | Aug 16, 2018 | Oct 22, 2019 (actual) |
| NCT02461771 | Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD | Phase 1 | Completed | Jan 28, 2015 | Mar 8, 2016 (actual) |
| NCT02503332 | Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy | Phase 2 | Completed | Sep 24, 2015 | Jul 14, 2017 (actual) |
| NCT03465709 | Pegcetacoplan (APL-2) in Neovascular AMD | Phase 1/Phase 2 | Terminated | Feb 14, 2018 | Apr 5, 2019 (actual) |
FDA records (last 2 years)
- FDA New indication / efficacy supplement: EMPAVELI (pegcetacoplan) — NDA215014/11, Jul 28, 2025. Applicant at approval: Apellis Pharmaceuticals, Inc. source ↗
Raises and investors new
- InvestorListed in the portfolio of Sofinnova Investments (captured Oct 12, 2026). portfolio page ↗
Connect
See your connections at Apellis Pharmaceuticals on LinkedIn (search by name, results not checked)